1952. RSV disease burden among children under two years of age in the United States
Session: Poster Abstract Session: Clinical: Respiratory Track
Saturday, October 7, 2017
Room: Poster Hall CD
Posters
  • IDWeek_poster_ARRIOLA_092917.pdf (368.3 kB)
  • Background:

    Respiratory Syncytial Virus (RSV) is a major cause of respiratory hospitalizations in young children. Hospital discharge records have been used to estimate RSV-associated hospitalizations, but lacked individual-level laboratory-confirmed RSV data. We adapted an influenza-disease burden model that uses population-based surveillance and probabilistic multipliers to adjust for biases in disease detection to estimate RSV hospitalizations among children <2 years in the United States.

    Methods:

    From October 2014 through April 2015, we identified laboratory-confirmed RSV hospitalizations among children <2 years from 4 Influenza Hospitalization Surveillance Network (FluSurv-NET) sites. In addition, we identified the frequency and type of RSV testing performed among children with pre-selected RSV-associated acute respiratory illness (ARI) ICD-9 codes at each surveillance hospital. We used the surveillance catchment population (309,000 children aged <2 years) to estimate age-specific (i.e., 0-2, 3-5, 6-11 and 12-23 months) rates of RSV-associated hospitalization, adjusting for detection probabilities. We then extrapolated these rates to the U.S. population using census data.

    Results:

    For the 2014-15 season, we identified 1,554 RSV-associated hospitalizations in children <2 years. Overall, 16%, 22%, 24% and 29% of children with RSV-associated ARI codes, aged 0-2, 3-5, 6-11, and 12-23 months, respectively, were not tested for RSV during hospitalization. The age-specific adjusted RSV hospitalization rates per 100,000 population were 1,970 (95% confidence interval (CI):1,757–2,184), 897 (95% CI: 723­–1,070), 531 (95% CI: 439–622), and 358 (95% CI: 311–405), for children aged 0-2, 3-5, 6-11, and 12-23 months, respectively. Extrapolating to the U.S. population, an estimated 50,705-67,021 RSV-associated hospitalizations occurred in children <2 years.

    Conclusion:

    Our findings reiterate the importance of RSV as a cause of hospitalization in young children, especially those aged 0-2 months. This probabilistic approach can produce annual estimates of RSV disease burden to inform public health interventions and prevention strategies including RSV vaccines and monoclonal antibodies.

    Carmen Arriola, DVM, PhD1, Carrie Reed, PhD1, Susan I. Gerber, MD2, Gayle E. Langley, MD, MPH3, Kristen Allen, MPH4, Evan J. Anderson, MD5, Kyle Openo, MPH6, Ruth Lynfield, MD, FIDSA7, Erica Bye, MPH8, Arthur Reingold, MD, FIDSA9, Pam Daily, MPH10, Ann Thomas, MD, MPH11, Courtney Crawford, MPH12, Shikha Garg, MD, MPH1 and Sandra S. Chaves, MD, MSc1, (1)Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, (2)Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, (3)Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, (4)Centers for Disease Control and Prevention, Atlanta, GA, (5)Pediatrics and Medicine, Emory University School of Medicine, Atlanta, GA, (6)Georgia Emerging Infections Program, Atlanta, GA, (7)State Epidemiologist and Medical Director for Infectious Diseases, Epidemiology & Community Health, Minnesota Department of Health, St. Paul, MN, (8)Minnesota Department of Health, St Paul, MN, (9)University of California - Berkeley, Berkeley, CA, (10)California Emerging Infections Program, Oakland, CA, (11)Oregon Public Health Division, Portland, OR, (12)Acute and Communicable Disease Prevention Section, Oregon Health Authority, Portland, OR

    Disclosures:

    C. Arriola, None

    C. Reed, None

    S. I. Gerber, None

    G. E. Langley, None

    K. Allen, None

    E. J. Anderson, AbbVie: Consultant , Consulting fee
    NovaVax: Research Contractor , Research support
    Regeneron: Research Contractor , Research grant
    MedImmune: Research Contractor , Research grant and Research support

    K. Openo, None

    R. Lynfield, None

    E. Bye, None

    A. Reingold, None

    P. Daily, None

    A. Thomas, None

    C. Crawford, None

    S. Garg, None

    S. S. Chaves, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.